0,1
Section 7.3.3 Summary of evidence and recommendations for the treatment of metastatic UTUC:,
Recommendations,Strength rating
"New 2023 recommendation: Offer adjuvant platinum-based chemotherapy after RNU 
to patients with pT2â€“T4 and/or pN+ disease.",Strong
"New 2023 recommendation: Discuss adjuvant nivolumab with patients unfit 
for, or who declined, platinum-based adjuvant chemotherapy for > pT3 and/or 
pN+ disease after RNU alone or > ypT2 and/or ypN+ disease after neoadjuvant 
chemotherapy, followed by RNU.",Weak
"2022 recommendation: Offer kidney-sparing management to patients with solitary 
kidney and/or impaired renal function, providing that it will not compromise survival. 
This decision will have to be made on a case-by-case basis in consultation with the 
patient.",Strong
"Revised 2023 recommendation: Offer kidney-sparing management to high-risk 
patients with imperative indication on a case-by-case basis, in consultation with the 
patient.",Strong
"Erdafitinib was associated with radiological response in platinum-refractory patients with 
locally-advanced or metastatic UC and FGFR DNA genomic alterations (FGFR2/3 mutations 
or FGFR3 fusions).",2a
"Enfortumab vedotin was associated with OS benefit in patients who had previously received 
platinum-containing chemotherapy and experienced disease progression during or after 
treatment with a PD-1 or PD-L1 inhibitor.",1b
Palliative nephroureterectomy can improve quality of life by controlling symptomatic disease.,3
RNU can confer a survival benefit in highly selected patients.,4
"Recommendations
Strength rating",
First-line treatment for cisplatin-eligible patients,
"New 2023 recommendation: Offer platinum combination chemotherapy to platinum-
Strong
eligible patients.",
First-line treatment in patients ineligible for cisplatin or carboplatin,
"New 2023 recommendation: Offer gemcitabine/carboplatin chemotherapy to 
cisplatin-ineligible patients.",Strong
"2022 recommendation: Offer checkpoint inhibitors pembrolizumab or atezolizumab 
depending on PD-L1 status.",Weak
"Revised 2023 recommendation: Offer checkpoint inhibitors pembrolizumab or 
atezolizumab to patients with PD-L1 positive tumours.",Weak
Second-line treatment,
"New 2023 recommendation: Offer enfortumab vedotin to patients previously treated 
with platinum-containing chemotherapy and who had disease progression during or 
after treatment with a PD-1 or PD-L1 inhibitor.",Strong
"2022 recommendation: Offer erdafitinib in platinum-refractory tumours with FGFR 
alterations.",Strong
"Revised 2023 recommendation: Offer erdafitinib as subsequent-line therapy 
to platinum-refractory patients with FGFR DNA genomic alterations (FGFR2/3 
mutations or FGFR3 fusions).",Weak
